Loading
The chemist whose lab found the hidden pocket in KRAS G12C that made the 'undruggable' target druggable.
Kevan Shokat is Professor of Cellular and Molecular Pharmacology at UCSF, within the UCSF Helen Diller Family Comprehensive Cancer Center, and an Investigator of the Howard Hughes Medical Institute. A chemical biologist specialising in KRAS and kinase inhibitors, his 2013 discovery of covalent inhibitors binding the switch-II pocket of KRAS G12C made a target long called undruggable druggable and opened the path to sotorasib and adagrasib. His papers include the Nature report that K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions and the Nature paper on a chemical switch for inhibitor-sensitive alleles of any protein kinase, the bump-hole approach. His work bears on lung, colorectal and pancreatic cancer.
Shares Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable, KRAS G12C-mutant pancreatic ductal adenocarcinoma, Sotorasib, KRAS & RAS inhibitors.
Shares Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable, Adagrasib, Sotorasib, KRAS G12C-mutant non-small-cell lung cancer.
Shares Adagrasib, Sotorasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, KRAS.
Shares Adagrasib, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Shares Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable, Adagrasib, KRAS G12C-mutant pancreatic ductal adenocarcinoma, Sotorasib.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pancreatic ductal adenocarcinoma.
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, KRAS.